Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
Hepatocellular carcinoma · PD-1/PD-L1 inhibitor · PD-1/PD-L1 inhibitor · PD-L1 expression · Tumor microenvironment · Tumor-infiltrating lymphocytes · stimulatory dendritic cells · conventional dendritic cells · tumor-associated macrophages · Single-cell RNA sequencing · spatial transcriptomics · Tumor heterogeneity · next-generation sequencing · tumor mutational burden · copy number alterations · TP53 · CTNNB1 · GZMB · Wnt/β-catenin signaling pathway · Child-Pugh class · Performance status · TGF-β signaling · Lactate dehydrogenase (LDH) · alpha-fetoprotein · Des-gamma-carboxyprothrombin · CRAFITY score · liquid biopsy · gut microbiome · EOB-MRI · PET/CT
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459